Mentalization for Offending Adult Males (MOAM): study protocol for a randomized controlled trial to evaluate mentalization-based treatment for antisocial personality disorder in male offenders on community probation.

Aggression Antisocial personality disorder Economic evaluation Mentalization-based treatment Offenders Patient and public involvement Personality disorder Probation Randomized controlled trial Violence

Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
07 Dec 2020
Historique:
received: 17 07 2020
accepted: 12 11 2020
entrez: 8 12 2020
pubmed: 9 12 2020
medline: 22 6 2021
Statut: epublish

Résumé

Antisocial personality disorder (ASPD), although associated with very significant health and social burden, is an under-researched mental disorder for which clinically effective and cost-effective treatment methods are urgently needed. No intervention has been established for prevention or as the treatment of choice for this disorder. Mentalization-based treatment (MBT) is a psychotherapeutic treatment that has shown some promising preliminary results for reducing personality disorder symptomatology by specifically targeting the ability to recognize and understand the mental states of oneself and others, an ability that is compromised in people with ASPD. This paper describes the protocol of a multi-site RCT designed to test the effectiveness and cost-effectiveness of MBT for reducing aggression and alleviating the wider symptoms of ASPD in male offenders subject to probation supervision who fulfil diagnostic criteria for ASPD. Three hundred and two participants recruited from a pool of offenders subject to statutory supervision by the National Probation Service at 13 sites across the UK will be randomized on a 1:1 basis to 12 months of probation plus MBT or standard probation as usual, with follow-up to 24 months post-randomization. The primary outcome is frequency of aggressive antisocial behaviour as assessed by the Overt Aggression Scale - Modified. Secondary outcomes include violence, offending rates, alcohol use, drug use, mental health status, quality of life, and total service use costs. Data will be gathered from police and criminal justice databases, NHS record linkage, and interviews and self-report measures administered to participants. Primary analysis will be on an intent-to-treat basis; per-protocol analysis will be undertaken as secondary analysis. The primary outcome will be analysed using hierarchical mixed-effects linear regression. Secondary outcomes will be analysed using mixed-effects linear regression, mixed-effects logistic regression, and mixed-effects Poisson models for secondary outcomes depending on whether the outcome is continuous, binary, or count data. A cost-effectiveness and cost-utility analysis will be undertaken. This definitive, national, multi-site trial is of sufficient size to evaluate MBT to inform policymakers, service commissioners, clinicians, and service users about its potential to treat offenders with ASPD and the likely impact on the population at risk. ISRCTN 32309003 . Registered on 8 April 2016.

Sections du résumé

BACKGROUND BACKGROUND
Antisocial personality disorder (ASPD), although associated with very significant health and social burden, is an under-researched mental disorder for which clinically effective and cost-effective treatment methods are urgently needed. No intervention has been established for prevention or as the treatment of choice for this disorder. Mentalization-based treatment (MBT) is a psychotherapeutic treatment that has shown some promising preliminary results for reducing personality disorder symptomatology by specifically targeting the ability to recognize and understand the mental states of oneself and others, an ability that is compromised in people with ASPD. This paper describes the protocol of a multi-site RCT designed to test the effectiveness and cost-effectiveness of MBT for reducing aggression and alleviating the wider symptoms of ASPD in male offenders subject to probation supervision who fulfil diagnostic criteria for ASPD.
METHODS METHODS
Three hundred and two participants recruited from a pool of offenders subject to statutory supervision by the National Probation Service at 13 sites across the UK will be randomized on a 1:1 basis to 12 months of probation plus MBT or standard probation as usual, with follow-up to 24 months post-randomization. The primary outcome is frequency of aggressive antisocial behaviour as assessed by the Overt Aggression Scale - Modified. Secondary outcomes include violence, offending rates, alcohol use, drug use, mental health status, quality of life, and total service use costs. Data will be gathered from police and criminal justice databases, NHS record linkage, and interviews and self-report measures administered to participants. Primary analysis will be on an intent-to-treat basis; per-protocol analysis will be undertaken as secondary analysis. The primary outcome will be analysed using hierarchical mixed-effects linear regression. Secondary outcomes will be analysed using mixed-effects linear regression, mixed-effects logistic regression, and mixed-effects Poisson models for secondary outcomes depending on whether the outcome is continuous, binary, or count data. A cost-effectiveness and cost-utility analysis will be undertaken.
DISCUSSION CONCLUSIONS
This definitive, national, multi-site trial is of sufficient size to evaluate MBT to inform policymakers, service commissioners, clinicians, and service users about its potential to treat offenders with ASPD and the likely impact on the population at risk.
TRIAL REGISTRATION BACKGROUND
ISRCTN 32309003 . Registered on 8 April 2016.

Identifiants

pubmed: 33287865
doi: 10.1186/s13063-020-04896-w
pii: 10.1186/s13063-020-04896-w
pmc: PMC7720544
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1001

Subventions

Organisme : Department of Health
ID : 14/186/01
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : 14/186/01

Références

Neuropsychopharmacology. 2003 Jun;28(6):1186-97
pubmed: 12700713
Crim Behav Ment Health. 2011 Jul;21(3):189-201
pubmed: 21452338
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Assessment. 2001 Dec;8(4):443-54
pubmed: 11785588
Crim Behav Ment Health. 2010 Apr;20(2):112-28
pubmed: 20352648
Arch Gen Psychiatry. 2007 Apr;64(4):476-84
pubmed: 17404124
J Clin Psychol. 2008 Feb;64(2):181-94
pubmed: 18186112
J Child Psychol Psychiatry. 1996 Jul;37(5):507-18
pubmed: 8807431
PLoS One. 2016 Jul 08;11(7):e0158678
pubmed: 27392018
J Consult Clin Psychol. 2011 Feb;79(1):6-21
pubmed: 21261430
Clin Psychol Rev. 2010 Apr;30(3):277-87
pubmed: 20047783
J Adolesc. 2002 Apr;25(2):221-30
pubmed: 12069436
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
Psychosomatics. 1996 Mar-Apr;37(2):131-6
pubmed: 8742541
Compr Psychiatry. 2005 Sep-Oct;46(5):371-9
pubmed: 16122538
Br J Psychiatry. 2003 Sep;183:190-2
pubmed: 12948988
Psychol Med. 2004 Aug;34(6):1093-102
pubmed: 15554579
Pediatrics. 2011 May;127(5):842-8
pubmed: 21518714
Psychol Bull. 1996 Mar;119(2):322-48
pubmed: 8851276
J Clin Psychol. 1998 Nov;54(7):973-83
pubmed: 9811134
Acta Psychiatr Scand Suppl. 1994;376:63-70
pubmed: 8178687
Arch Gen Psychiatry. 1996 Jun;53(6):489-96
pubmed: 8639031
Clin Trials. 2005;2(2):152-62
pubmed: 16279137
Dev Psychopathol. 1997 Fall;9(4):679-700
pubmed: 9449001
Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
BMJ. 2000 Apr 29;320(7243):1197-200
pubmed: 10784550
Arch Gen Psychiatry. 1985 Jan;42(1):47-54
pubmed: 3966852
J Pers Disord. 1997 Fall;11(3):279-84
pubmed: 9348491
J Pers Disord. 2017 Apr;31(2):232-255
pubmed: 27064853
Crim Behav Ment Health. 2015 Dec;25(5):403-15
pubmed: 25234316
J Consult Clin Psychol. 2012 Dec;80(6):1114-20
pubmed: 23025249
Br J Psychiatry Suppl. 2007 May;49:s75-8
pubmed: 17470946
Am J Epidemiol. 2006 Dec 15;164(12):1199-208
pubmed: 17032695
Int J Law Psychiatry. 2014 Jul-Aug;37(4):334-40
pubmed: 24684784
Stat Med. 2000 Dec 15;19(23):3219-36
pubmed: 11113956
J Neurol Neurosurg Psychiatry. 2001 Dec;71(6):727-31
pubmed: 11723191
Ann N Y Acad Sci. 2004 Dec;1036:215-32
pubmed: 15817740
Int J Psychoanal. 1991;72 ( Pt 4):639-56
pubmed: 1797718
Crim Behav Ment Health. 2013 Oct;23(4):274-89
pubmed: 24101409
Cochrane Database Syst Rev. 2010 Aug 04;(8):CD007667
pubmed: 20687091
Psychosom Med. 2014 May;76(4):311-7
pubmed: 24804880
Arch Gen Psychiatry. 1998 May;55(5):393-401
pubmed: 9596041
J Child Psychol Psychiatry. 2009 May;50(5):607-16
pubmed: 19207633
Neurosci Biobehav Rev. 2008;32(3):454-65
pubmed: 17915324
Psychol Med. 2009 Apr;39(4):569-77
pubmed: 18667099
J Abnorm Child Psychol. 2013 Aug;41(6):929-38
pubmed: 23512713
J Ment Health. 2002;11(2):191-8
pubmed: 21208145
J Clin Psychiatry. 2005 Jun;66(6):677-85
pubmed: 15960559
Stat Med. 2011 Apr 30;30(9):922-34
pubmed: 21284014
Drug Alcohol Depend. 2013 Sep 1;132(1-2):373-7
pubmed: 23394688
Ann N Y Acad Sci. 2004 Dec;1036:181-200
pubmed: 15817738
Biol Psychiatry. 2007 Sep 15;62(6):553-64
pubmed: 17217923
BMJ. 2007 Oct 27;335(7625):837
pubmed: 17962244
Med Sci Monit. 2005 Jul;11(7):CR317-25
pubmed: 15990689
Eur Addict Res. 2005;11(1):22-31
pubmed: 15608468
BMJ. 2011 Feb 07;342:d40
pubmed: 21300711
Cortex. 2010 May;46(5):668-77
pubmed: 19501818
Br J Psychiatry. 2013 Sep;203(3):221-7
pubmed: 23887998
Psychiatry Res. 2003 Feb 15;117(2):159-66
pubmed: 12606017
J Pers Disord. 2012 Oct;26(5):775-92
pubmed: 23013345
Br J Psychiatry. 2007 Apr;190:307-13
pubmed: 17401036
J Pers Disord. 2008 Jun;22(3):259-68
pubmed: 18540798
Attach Hum Dev. 2007 Sep;9(3):223-37
pubmed: 18058431
Aust N Z J Psychiatry. 2006 Jun-Jul;40(6-7):519-28
pubmed: 16756576
Law Hum Behav. 2008 Dec;32(6):511-25
pubmed: 18080733

Auteurs

Peter Fonagy (P)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK. p.fonagy@ucl.ac.uk.
Anna Freud National Centre for Children and Families, London, UK. p.fonagy@ucl.ac.uk.

Jessica Yakeley (J)

Portman Clinic, Tavistock and Portman NHS Foundation Trust, London, UK.

Tessa Gardner (T)

Anna Freud National Centre for Children and Families, London, UK.

Elizabeth Simes (E)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.
Anna Freud National Centre for Children and Families, London, UK.

Mary McMurran (M)

Institute of Mental Health, University of Nottingham, Nottingham, UK.

Paul Moran (P)

Centre for Academic Mental Health, Population Health Sciences Department, Bristol Medical School, University of Bristol, Bristol, UK.

Mike Crawford (M)

Centre for Mental Health, Imperial College, London, UK.

Alison Frater (A)

School of Law, Royal Holloway, University of London, London, UK.

Barbara Barrett (B)

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Angus Cameron (A)

National Probation Service London Division, London, UK.

James Wason (J)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

Stephen Pilling (S)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.

Stephen Butler (S)

Psychology Department, University of Prince Edward Island, Charlottetown, Canada.

Anthony Bateman (A)

Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.
Anna Freud National Centre for Children and Families, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH